薛俊丽 副主任医师，讲师
硕士招生类型：学术型；专业型
硕士招生专业：肿瘤学
博士招生类型：
博士招生专业：
所在院系：附属东方医院
联系方式：**xuejunli@tongji.edu.cn
课题组链接：
研究方向
主要任职
科研业绩

1.PIPKIγ在胃肠道肿瘤有氧糖酵解作用及机制( role of PIPKIgamma in GIcancer and possible mechanism)
2.外泌体在消化道肿瘤治疗中的作用( role of exosome in GIcancer)
3.新药I期临床研究( anti-cancer new drugphase I clinical trial)




中国临床肿瘤学会（CSCO）药物安全管理专家委员会 秘书
Secretaryof Anti-cancer drug Safety Management Committee (ASMC), CSCO
中国临床肿瘤学会（CSCO）青年委员会 委员
Committeemember of CSCO YOUNG
中国临床肿瘤学会（CSCO）青年委员会 翻译小组成员
Memberof CSCO YOUNG translation group
中国临床肿瘤学会（CSCO）患者教育委员会 常委
Memberof the standing committee of CSCO patients education committee
《肿瘤学杂志》 青年编委
Youtheditor of
《肿瘤综合治疗电子杂志》 编委
Editorof



承担课题
2 2018年 北京医卫健康公益基金会，安罗替尼在晚期胃癌一线治疗中安全性及有效性观察Ib期临床研究，起止时间：2018.7-2021.06；10万，在研，主持；
2 2018年 东方医院旭日人才计划，10万元；
2 2017年 科技部慢性重大疾病防治计划，靶向药物治疗胃癌的早期临床研究及多中心大样本临床研究，起止时间：2017.7-2020.12；77万，在研，课题骨干；
2 2017年 上海市科委引导项目，甲氨蝶呤片临床等效性研究与质量评价，起止时间：2017.7-2020.6；20万，在研，主持；
2 2015年 国家自然科学基金青年科学基金项目，项目编号：**，项目名称：干预PIPKIγ通过调节γ-catenin影响乳腺癌循环肿瘤细胞簇形成及机制研究，起止时间：2016.01-2018-12；19.6万，在研，主持；
2 2014年 上海市卫生和计划生育委员会科研课题 面上项目，项目编号：，项目名称：乳腺癌中干细胞表型循环肿瘤细胞(CTCs)与肿瘤转移和预后关系及初步机制探讨，起止时间：2015.01-2017.12；3万，已结题，主持；
2 2014年 入选上海青年医师培养资助计划（上海市卫生和计划生育委员会），已结题；
2 2013年 东方朝阳人才计划，项目编号：DFZY-12，项目名称：循环肿瘤细胞（CTC）与胃癌肿瘤相关高凝状态的相关关系研究，起止时间：2013.11-2015.10；3万，已结题，主持。
Funding Information
Current
1. 2018.07-2021.06 Title:phase I clinical trial of Anlotinib in advanced grastric cancer first linetreatment
Grant NO.: PI (￥100,000)
Major goal: to investigate the safety andeffecacy of Anlotinib in advanced gastric cancer treatment.
2. 2018.01-2020.12 Title: Sunrise plan ofEast Hospital, (￥100,000)
3. 2017.07-2020.12 Title: targetedtreatment for gastric cancer: early clinical trial and multi-center clinicaltrial
Grant NO.: 2017YFC** (￥770,000)
Major goal: to find new effective targetfor gastric cancer treament and investigate new drug for gastric cancer.
4. 2017.07-2020.06 Title: bioequivalenceresearch of Methotrexate in clinical use
Grant NO.: PI ** (￥200,000)
Major goal: to investigate thebioequivalence of Chinese methotrexate and to promote Chinese drug come intomarket.
Past
1. 5. 2016.01-2018.12 Title:Role of PIPKIγ intervention in breast cancer CTC Cluster formation viaregulating γ-catenin and its possible mechanism
Grant NO.: ** ((￥198,000)
Major goal: to demonstrate the possibleprognostic and therapeutic role of PIPKIγ in breast cancer, providing novel wayfor breast cancer early diagnosis and therapy.
2. 2015.01-2017.12 Title:the role of CSC in breast cancer metastasis and prognosis, possible mechanism
Grant NO.: PI (￥30,000)
Major goal: to reveal the role of CSCphenotype CTCs during the breast cancer metastasis, and take effective measureto prevent the metastasis and improve patients prognosis
3. 2014.07-2017.07 Title:Shanghai Outstanding Youth Doctor program
PI (￥100,000)
4. 2013.11-2016.10 Title:The Relationship of CTC and Coagulation Situation in Gastric Cancer Patients
Grant NO.: DFZY-12 PI (￥30,000)
Major goal: We will find the relationshipbetween CTC and coagulation situation and thrombosis in Gastric cancerpatients, and whether anticoagulation may treatment could control or preventcancer metastasis

发表论文
1. WeiPeng, Wei Huang, Liqiong Xue, Xiaoxiao Ge, Wei Zhao, Junli Xue#. Type Iγphosphatidylinositol phosphate kinase promotes tumor growth by facilitatingWarburg effect in colorectal cancer. EBioMedicine, 2019, 44: 375-386.
2. JunliXue,Xuetao Yu?, ?Liqiong Xue, Xiaoxiao Ge, Wei Zhao, Wei Peng. Intrinsic β-cateninsignaling suppresses CD8?+ T-cell infiltration in colorectal cancer. Biomedicine& Pharmacotherapy. 2019, 115: 108921.
3. JunliXue,Chunhua Chen, Manlong Qi, Kun Ling. Type Iγ phosphatidylinositol phosphatekinase regulates PD-L1 expression by activating NF-κB., Oncotarget, 2017.6.27,8(26): 42414~42427.
4. XingJiang, Yong Zhou, Ai-Jun Sun, Jun-Li Xue# NEAT1 contributes to breastcancer progression through modulating miR-448 and ZEB1, J Cell Physiol, 2018,233(11):8558-8566.
5. JunliXue,Victoria K. Xie, Peipei Wang, Jiujie Cui, Yong Gao, and Zhimin Lu. Interrelationshipsof Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs. CurrPharm Des. 2014; 20(33): 5298–5308.
6. Chen,Chunhua; Wang, Xiangling; Fang, Juemin; Xue, Junli; Xiong, Xunhao;Huang, Yan; Hu, Jinghua; Ling, Kun# EGFR-induced phosphorylation of type Igamma phosphatidylinositol phosphate kinase promotes pancreatic cancer progression,ONCOTARGET, 2017.6.27, 8(26): 42621~42637.
7. Cao,Siyu; Chen, Chunhua; Xue, Junli; Huang, Yan; Yang, Xiaofeng Ling, KunSilencing of type I gamma phosphatidylinositol phosphate kinase suppressesovarian cancer cell proliferation, migration and invasion, ONCOLOGY REPORTS,2017.7, 38(1): 253~262.
8. JiangH, Lin Y, Yang CQ, Li Q, Luo J, Zhou Y, Xue JL, Wei W, Gao Y. Quantitativeassessment of the association between XRCC6 C1310G polymorphism and cancerrisk. Tumour Biol. 2013 Apr;34(2):779-85.
9. Feng B,Yan XF, Xue JL, Xu L, Wang H. The Protective Effects of α-Lipoic Acid onKidneys in Type 2 Diabetic Goto-Kakisaki Rats via Reducing Oxidative Stress. Int.J. Mol. Sci. 2013, 14, 6746-6756.